Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 9 (2) , 133-136
- https://doi.org/10.3109/07357909109044223
Abstract
Based on results of previous Phase I studies, 18 patients with documented metastastic renal cell carcinoma received Taxol 250 mg/m2 as a 24-h infusion, repeated every 21 days in this Phase II study. All patients received premedication with dexamethasone, diphenhydramine, and cimetidine. There were no responses in the 18 patients treated.Keywords
This publication has 13 references indexed in Scilit:
- Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.Journal of Clinical Oncology, 1987
- Phase I study of taxol using a 5-day intermittent schedule.Journal of Clinical Oncology, 1986
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- Current Therapy for Renal Cell CarcinomaJournal of Urology, 1982
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980
- Promotion of microtubule assembly in vitro by taxolNature, 1979
- Current status of the therapy of advanced renal carcinomaJournal of Surgical Oncology, 1977
- Chemotherapy of adenocarcinoma of the kidneyCancer, 1973
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971
- The Current Status of Chemotherapy for Advanced Renal CarcinomaJournal of Urology, 1967